Over the last decades, significant improvements in reducing the toxicities of allogeneic hematopoietic cell transplantation (allo-HCT) have widened its use as consolidation or salvage therapy for high-risk hematological malignancies. Nevertheless, relapse of the original malignant disease remains an open issue, with unsatisfactory salvage options and limited rationales to select amongst them. In the last years, a number of studies have highlighted that relapse is often associated to …